vorinostat has been researched along with Carcinoma, Non-Small Cell Lung in 65 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma." | 9.16 | Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012) |
| "Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma." | 5.16 | Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012) |
| "Vorinostat dose levels were 200, 300, and 400 mg orally once daily for 14 days." | 2.84 | Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. ( Adler, JR; Chang, SD; Choi, CYH; Harsh, GR; Modlin, LA; Neal, JW; Pinder-Schenck, MC; Soltys, SG; Wakelee, HA; Yu, HM, 2017) |
| "Vorinostat has been shown to overcome resistance to gefitinib." | 2.80 | Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. ( Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T, 2015) |
| "Vorinostat was administrated by mouth, once daily, Monday through Friday, concurrently with radiation treatment." | 2.79 | Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. ( Andrews, DW; Bar-Ad, V; Berger, AC; Choy, H; Dicker, AP; Evans, JJ; Farrell, CJ; Judy, KD; Lawrence, YR; Moshel, Y; Shi, W; Werner-Wasik, M, 2014) |
| "Vorinostat is an inhibitor of histone deacetylase 6, which acetylates tubulin and stabilizes microtubules." | 2.77 | Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. ( Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC, 2012) |
| "Vorinostat or placebo was given on days 1 through 14 of each 3-week cycle to a maximum of six cycles." | 2.75 | Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. ( Argiris, AE; Belani, CP; Espinoza-Delgado, I; Frankel, P; Gandara, DR; Gitlitz, B; Koczywas, M; Maitland, ML; Ramalingam, SS; Thomas, S; Vokes, EE, 2010) |
| "Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC)." | 2.74 | Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. ( Dubey, S; Eickhoff, JC; Espinoza-Delgado, I; Groteluschen, DL; Hallahan, CM; Huie, MS; Kolesar, JM; Marcotte, SM; Schell, K; Schiller, JH; Traynor, AM; Weeks, HR; Wilding, G, 2009) |
| "Vorinostat (Zolinza) is a histone deacetylase inhibitor that has demonstrated activity in patients with advanced solid tumors in phase I trials." | 2.73 | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. ( Chen, C; Dumez, H; Randolph, SS; Ricker, JL; Schöffski, P; Van Cutsem, E; Vansteenkiste, J, 2008) |
| "Lung cancer is a leading cause of cancer-related mortality worldwide, and concurrent chemoradiotherapy has been explored as a therapeutic option." | 1.43 | Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. ( Chen, X; Feng, J; Huang, H; Jiang, H; Ma, S; Wang, B; Wong, JY; Wu, K; Xu, R; Ying, L; Zhang, S; Zheng, X, 2016) |
| "Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor." | 1.43 | Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016) |
| "Treatment with vorinostat activated IGF-1R signaling in vorinostat-resistant but not vorinostat-sensitive NSCLC cells." | 1.42 | Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. ( Choi, SP; Hyun, SY; Kim, JS; Kim, WY; Kwon, SJ; Lee, HJ; Lee, HY; Lee, SC; Min, HY; Park, KH, 2015) |
| " In xenograft models, while gefitinib induced marked regression via apoptosis of tumors without the BIM polymorphism, its combination with vorinostat was needed to induce marked regression of tumors with the BIM polymorphism in the same manner." | 1.39 | EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. ( Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S, 2013) |
| "The development of lung cancer is associated with silencing tumor suppressor genes that can occur not only by deletion or mutation, but also by epigenetic changes including histone deacetylation of key lysines." | 1.33 | SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. ( Chien, W; Kawamata, N; Koeffler, HP; Komatsu, N; Miller, CW; Takeuchi, S; Yin, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (26.15) | 29.6817 |
| 2010's | 41 (63.08) | 24.3611 |
| 2020's | 7 (10.77) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, M | 1 |
| Rivault, F | 1 |
| Tranoy-Opalinski, I | 1 |
| Roche, J | 2 |
| Gesson, JP | 2 |
| Papot, S | 1 |
| Charrier, C | 1 |
| Bertrand, P | 1 |
| Yu, CW | 1 |
| Hung, PY | 1 |
| Yang, HT | 1 |
| Ho, YH | 1 |
| Lai, HY | 1 |
| Cheng, YS | 1 |
| Chern, JW | 1 |
| Ojha, R | 1 |
| Nepali, K | 1 |
| Chen, CH | 1 |
| Chuang, KH | 1 |
| Wu, TY | 1 |
| Lin, TE | 1 |
| Hsu, KC | 1 |
| Chao, MW | 1 |
| Lai, MJ | 1 |
| Lin, MH | 1 |
| Huang, HL | 1 |
| Chang, CD | 1 |
| Pan, SL | 1 |
| Chen, MC | 1 |
| Liou, JP | 1 |
| Chae, HY | 1 |
| Park, SY | 1 |
| Jha, S | 1 |
| Gupta, SK | 1 |
| Kim, M | 1 |
| Ha, E | 1 |
| Seo, YH | 1 |
| Gray, JE | 1 |
| Saltos, A | 1 |
| Tanvetyanon, T | 1 |
| Haura, EB | 1 |
| Creelan, B | 1 |
| Antonia, SJ | 1 |
| Shafique, M | 1 |
| Zheng, H | 1 |
| Dai, W | 1 |
| Saller, JJ | 1 |
| Chen, Z | 1 |
| Tchekmedyian, N | 1 |
| Goas, K | 1 |
| Thapa, R | 1 |
| Boyle, TA | 1 |
| Chen, DT | 1 |
| Beg, AA | 1 |
| Takeuchi, S | 5 |
| Hase, T | 1 |
| Shimizu, S | 2 |
| Ando, M | 2 |
| Hata, A | 1 |
| Murakami, H | 1 |
| Kawakami, T | 1 |
| Nagase, K | 2 |
| Yoshimura, K | 2 |
| Fujiwara, T | 2 |
| Tanimoto, A | 2 |
| Nishiyama, A | 1 |
| Arai, S | 2 |
| Fukuda, K | 2 |
| Katakami, N | 2 |
| Takahashi, T | 2 |
| Hasegawa, Y | 3 |
| Ko, TK | 1 |
| Ong, ST | 2 |
| Yano, S | 4 |
| Wu, PF | 1 |
| Gao, WW | 1 |
| Sun, CL | 1 |
| Ma, T | 1 |
| Hao, JQ | 1 |
| Tu, B | 1 |
| He, Y | 2 |
| Chen, B | 1 |
| Wang, Y | 2 |
| Gao, Y | 1 |
| Shi, M | 1 |
| Liu, T | 2 |
| Asrorov, AM | 1 |
| Huang, Y | 1 |
| Yang, H | 1 |
| Sun, B | 1 |
| Xu, K | 1 |
| Zhang, T | 1 |
| Hall, SRR | 1 |
| Tan, ST | 1 |
| Schmid, RA | 1 |
| Peng, RW | 1 |
| Hu, G | 1 |
| Yao, F | 1 |
| Liu, F | 1 |
| Fang, C | 1 |
| Xu, L | 1 |
| Chen, L | 1 |
| Xu, Z | 1 |
| Chen, J | 1 |
| Peng, W | 1 |
| Fu, B | 1 |
| Li, Y | 1 |
| Choi, CYH | 1 |
| Wakelee, HA | 1 |
| Neal, JW | 1 |
| Pinder-Schenck, MC | 1 |
| Yu, HM | 1 |
| Chang, SD | 1 |
| Adler, JR | 1 |
| Modlin, LA | 1 |
| Harsh, GR | 1 |
| Soltys, SG | 1 |
| Inoue, A | 1 |
| Wei, Y | 1 |
| Zhou, F | 1 |
| Lin, Z | 1 |
| Shi, L | 1 |
| Huang, A | 1 |
| Yu, D | 1 |
| Wu, G | 1 |
| Jeannot, V | 1 |
| Gauche, C | 1 |
| Mazzaferro, S | 1 |
| Couvet, M | 1 |
| Vanwonterghem, L | 1 |
| Henry, M | 1 |
| Didier, C | 1 |
| Vollaire, J | 1 |
| Josserand, V | 2 |
| Coll, JL | 2 |
| Schatz, C | 1 |
| Lecommandoux, S | 1 |
| Hurbin, A | 2 |
| Park, SE | 1 |
| Kim, DE | 1 |
| Kim, MJ | 1 |
| Lee, JS | 2 |
| Rho, JK | 1 |
| Jeong, SY | 1 |
| Choi, EK | 1 |
| Kim, CS | 1 |
| Hwang, JJ | 1 |
| Hoang, T | 1 |
| Campbell, TC | 1 |
| Zhang, C | 1 |
| Kim, K | 1 |
| Kolesar, JM | 2 |
| Oettel, KR | 1 |
| Blank, JH | 1 |
| Robinson, EG | 1 |
| Ahuja, HG | 1 |
| Kirschling, RJ | 1 |
| Johnson, PH | 1 |
| Huie, MS | 2 |
| Wims, ME | 1 |
| Larson, MM | 1 |
| Hernan, HR | 1 |
| Traynor, AM | 2 |
| Wu, Q | 2 |
| Xu, W | 2 |
| Cao, L | 2 |
| Li, X | 1 |
| He, T | 1 |
| Wu, Z | 3 |
| Li, W | 2 |
| Reguart, N | 1 |
| Rosell, R | 1 |
| Cardenal, F | 1 |
| Cardona, AF | 1 |
| Isla, D | 1 |
| Palmero, R | 1 |
| Moran, T | 1 |
| Rolfo, C | 1 |
| Pallarès, MC | 1 |
| Insa, A | 1 |
| Carcereny, E | 1 |
| Majem, M | 1 |
| De Castro, J | 1 |
| Queralt, C | 1 |
| Molina, MA | 1 |
| Taron, M | 1 |
| Shi, W | 1 |
| Lawrence, YR | 1 |
| Choy, H | 1 |
| Werner-Wasik, M | 1 |
| Andrews, DW | 1 |
| Evans, JJ | 1 |
| Judy, KD | 1 |
| Farrell, CJ | 1 |
| Moshel, Y | 1 |
| Berger, AC | 1 |
| Bar-Ad, V | 1 |
| Dicker, AP | 1 |
| Han, JY | 1 |
| Lee, SH | 1 |
| Lee, GK | 1 |
| Yun, T | 1 |
| Lee, YJ | 1 |
| Hwang, KH | 1 |
| Kim, JY | 1 |
| Kim, HT | 1 |
| Kim, JS | 1 |
| Lee, SC | 2 |
| Min, HY | 2 |
| Park, KH | 2 |
| Hyun, SY | 2 |
| Kwon, SJ | 2 |
| Choi, SP | 1 |
| Kim, WY | 1 |
| Lee, HJ | 2 |
| Lee, HY | 2 |
| Kuo, WY | 1 |
| Wu, CY | 1 |
| Hwu, L | 1 |
| Tsai, CH | 1 |
| Lin, KP | 1 |
| Wang, HE | 1 |
| Chou, TY | 1 |
| Tsai, CM | 1 |
| Gelovani, J | 1 |
| Liu, RS | 1 |
| Cheng, Z | 1 |
| Zhu, J | 1 |
| Peng, X | 1 |
| Chen, C | 2 |
| Wang, F | 1 |
| Yi, X | 1 |
| Li, J | 1 |
| Fan, P | 1 |
| Hanke, NT | 1 |
| Garland, LL | 1 |
| Baker, AF | 1 |
| Leone, A | 2 |
| Roca, MS | 2 |
| Ciardiello, C | 2 |
| Terranova-Barberio, M | 1 |
| Vitagliano, C | 2 |
| Ciliberto, G | 2 |
| Mancini, R | 2 |
| Di Gennaro, E | 2 |
| Bruzzese, F | 2 |
| Budillon, A | 2 |
| Barr, MP | 1 |
| O'Byrne, KJ | 2 |
| Al-Sarraf, N | 2 |
| Gray, SG | 2 |
| Lee, E | 1 |
| Jin, D | 1 |
| Lee, BB | 1 |
| Kim, Y | 1 |
| Han, J | 1 |
| Shim, YM | 1 |
| Kim, DH | 1 |
| Liang, GK | 1 |
| Yao, ZT | 1 |
| Zhang, JQ | 1 |
| Chen, X | 3 |
| Liu, RY | 1 |
| Chen, HH | 1 |
| Wu, HH | 1 |
| Jin, L | 1 |
| Ding, L | 1 |
| Feng, J | 2 |
| Zhang, S | 2 |
| Wu, K | 2 |
| Wang, B | 1 |
| Wong, JY | 1 |
| Jiang, H | 1 |
| Xu, R | 1 |
| Ying, L | 1 |
| Huang, H | 2 |
| Zheng, X | 1 |
| Ma, S | 3 |
| Noto, A | 1 |
| Moccia, T | 1 |
| Roscilli, G | 1 |
| Aurisicchio, L | 1 |
| Marra, E | 1 |
| Liang, Y | 1 |
| Zeng, J | 1 |
| Jelicks, L | 1 |
| Liu, J | 1 |
| Mei, J | 1 |
| Perez-Soler, R | 1 |
| Zou, Y | 1 |
| Jung, HJ | 1 |
| Cho, J | 1 |
| Woo, JK | 1 |
| Johnson, FM | 1 |
| Takashina, T | 1 |
| Kinoshita, I | 1 |
| Kikuchi, J | 1 |
| Shimizu, Y | 1 |
| Sakakibara-Konishi, J | 1 |
| Oizumi, S | 1 |
| Nishimura, M | 1 |
| Dosaka-Akita, H | 1 |
| Deng, Q | 1 |
| Guo, C | 1 |
| Xia, B | 1 |
| Zhang, J | 1 |
| Zhu, L | 1 |
| Zhang, K | 1 |
| Shen, B | 1 |
| Yamada, T | 2 |
| Roca, X | 1 |
| Zhang, XH | 1 |
| Rao, M | 1 |
| Loprieato, JA | 1 |
| Hong, JA | 1 |
| Zhao, M | 1 |
| Chen, GZ | 1 |
| Humphries, AE | 1 |
| Nguyen, DM | 1 |
| Trepel, JB | 1 |
| Yu, X | 1 |
| Schrump, DS | 1 |
| Noro, R | 2 |
| Miyanaga, A | 2 |
| Shimokawa, T | 1 |
| Kuribayashi, H | 1 |
| Mizutani, H | 1 |
| Minegishi, Y | 2 |
| Okano, T | 2 |
| Seike, M | 2 |
| Soeno, C | 2 |
| Kataoka, K | 2 |
| Matsuda, K | 2 |
| Yoshimura, A | 2 |
| Gemma, A | 2 |
| Dubey, S | 1 |
| Eickhoff, JC | 1 |
| Schell, K | 1 |
| Groteluschen, DL | 1 |
| Marcotte, SM | 1 |
| Hallahan, CM | 1 |
| Weeks, HR | 1 |
| Wilding, G | 1 |
| Espinoza-Delgado, I | 2 |
| Schiller, JH | 1 |
| Owonikoko, TK | 1 |
| Ramalingam, SS | 2 |
| Kanterewicz, B | 1 |
| Balius, TE | 1 |
| Belani, CP | 2 |
| Hershberger, PA | 1 |
| Baird, AM | 1 |
| Cathcart, MC | 1 |
| McGovern, E | 1 |
| Busser, B | 1 |
| Sancey, L | 1 |
| Niang, C | 1 |
| Khochbin, S | 1 |
| Favrot, MC | 1 |
| Maitland, ML | 1 |
| Frankel, P | 1 |
| Argiris, AE | 1 |
| Koczywas, M | 1 |
| Gitlitz, B | 1 |
| Thomas, S | 1 |
| Vokes, EE | 1 |
| Gandara, DR | 1 |
| Kakihana, M | 1 |
| Ohira, T | 1 |
| Chan, D | 2 |
| Webster, RB | 1 |
| Kato, H | 1 |
| Drabkin, HA | 3 |
| Gemmill, RM | 2 |
| Schneider, BJ | 1 |
| Kalemkerian, GP | 1 |
| Bradley, D | 1 |
| Smith, DC | 1 |
| Egorin, MJ | 1 |
| Daignault, S | 1 |
| Dunn, R | 1 |
| Hussain, M | 1 |
| Nagji, AS | 1 |
| Cho, SH | 1 |
| Liu, Y | 1 |
| Lee, JK | 1 |
| Jones, DR | 5 |
| Kurtze, I | 1 |
| Sonnemann, J | 1 |
| Beck, JF | 1 |
| Seo, SK | 2 |
| Jin, HO | 2 |
| Woo, SH | 2 |
| Kim, YS | 1 |
| An, S | 2 |
| Lee, JH | 1 |
| Hong, SI | 2 |
| Lee, KH | 1 |
| Choe, TB | 2 |
| Park, IC | 2 |
| Chien, CW | 1 |
| Yao, JH | 1 |
| Chang, SY | 1 |
| Lee, PC | 1 |
| Lee, TC | 1 |
| Millward, M | 1 |
| Price, T | 1 |
| Townsend, A | 1 |
| Sweeney, C | 1 |
| Spencer, A | 1 |
| Sukumaran, S | 1 |
| Longenecker, A | 1 |
| Lee, L | 1 |
| Lay, A | 1 |
| Sharma, G | 1 |
| Lloyd, GK | 1 |
| Neuteboom, ST | 1 |
| McConkey, DJ | 1 |
| Palladino, MA | 1 |
| Spear, MA | 1 |
| Dasari, A | 1 |
| Gore, L | 1 |
| Messersmith, WA | 1 |
| Diab, S | 1 |
| Jimeno, A | 1 |
| Weekes, CD | 1 |
| Lewis, KD | 1 |
| Flaig, TW | 1 |
| Camidge, DR | 1 |
| Mateen, S | 1 |
| Raina, K | 1 |
| Jain, AK | 1 |
| Agarwal, C | 1 |
| Agarwal, R | 1 |
| Moskaluk, CA | 1 |
| Gillenwater, HH | 1 |
| Petroni, GR | 1 |
| Burks, SG | 1 |
| Philips, J | 1 |
| Rehm, PK | 1 |
| Olazagasti, J | 1 |
| Kozower, BD | 1 |
| Bao, Y | 1 |
| Nakagawa, T | 1 |
| Ebi, H | 1 |
| Sano, T | 1 |
| Nanjo, S | 1 |
| Ishikawa, D | 1 |
| Sato, M | 1 |
| Sekido, Y | 1 |
| Rundall, BK | 3 |
| Denlinger, CE | 3 |
| Komatsu, N | 1 |
| Kawamata, N | 1 |
| Yin, D | 1 |
| Chien, W | 1 |
| Miller, CW | 1 |
| Koeffler, HP | 1 |
| Imre, G | 1 |
| Gekeler, V | 1 |
| Leja, A | 1 |
| Beckers, T | 1 |
| Boehm, M | 1 |
| Lee, HC | 1 |
| Kim, ES | 1 |
| Yoo, DH | 1 |
| Lee, SJ | 1 |
| Rhee, CH | 1 |
| Tseng, RC | 1 |
| Lin, RK | 1 |
| Wen, CK | 1 |
| Tseng, C | 1 |
| Hsu, HS | 1 |
| Hsu, WH | 1 |
| Wang, YC | 1 |
| Gridelli, C | 1 |
| Rossi, A | 1 |
| Maione, P | 1 |
| Vansteenkiste, J | 1 |
| Van Cutsem, E | 1 |
| Dumez, H | 1 |
| Ricker, JL | 1 |
| Randolph, SS | 1 |
| Schöffski, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)[NCT01027676] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | ||
| A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.[NCT00126451] | Phase 2 | 16 participants (Actual) | Interventional | 2004-12-01 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Butyrates; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibi | 2008 |
15 trials available for vorinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
Topics: Aged; Aged, 80 and over; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Administration | 2020 |
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administratio | 2017 |
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lun | 2017 |
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Smal | 2014 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2014 |
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cohort Studies; Disease Pr | 2014 |
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2015 |
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Female; Histone Deac | 2009 |
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2010 |
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dru | 2012 |
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carci | 2012 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2013 |
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2012 |
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neop | 2008 |
49 other studies available for vorinostat and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cattle; Cell Line, Tumor; Cell Proli | 2007 |
Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; | 2007 |
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Topics: Acetylation; Animals; Apoptosis; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dr | 2019 |
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Li | 2020 |
Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Histone Deacetylas | 2022 |
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, | 2020 |
Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Liposomes; Lung Neoplasms; Simvastatin; Tumor Microenvironme | 2020 |
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung | 2021 |
Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC.
Topics: A549 Cells; Acetylation; Animals; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, T | 2021 |
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Histone D | 2018 |
Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Syst | 2018 |
Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; | 2019 |
SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Topics: Acetylation; Amino Acid Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; E | 2013 |
Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neop | 2015 |
Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Animals; Carcinoma, Non-Small-Cell Lung; Cell Self Renewal; | 2015 |
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Topics: Acetylation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analys | 2015 |
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose | 2016 |
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Dru | 2015 |
VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
Topics: Acetylation; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell S | 2015 |
Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cyclin D1 | 2015 |
[Statins enhance anti-tumor effect of suberoylanilide hydroxamic acid on human non-small cell lung carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferati | 2015 |
Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Mo | 2016 |
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Drug Syne | 2016 |
Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carcin | 2017 |
Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.
Topics: Acetylation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistanc | 2016 |
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Topics: Acetylation; Adenosine; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell P | 2016 |
Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cel | 2016 |
Histone Deacetylase 3 Inhibition Overcomes
Topics: Acrylamides; Aniline Compounds; Apoptosis; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Ce | 2017 |
Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Topics: Aurora Kinase B; Aurora Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, | 2008 |
The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2009 |
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemothera | 2010 |
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications.
Topics: Acetylation; Antineoplastic Agents; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; | 2009 |
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Prote | 2010 |
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Blotting, Western; Cadherins; | 2009 |
New treatment strategy enhances outcome for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinica | 2009 |
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cy | 2010 |
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoma, Non-Smal | 2010 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell | 2011 |
Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Topics: Acetylation; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Pr | 2011 |
Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinom | 2011 |
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Topics: Acetylation; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin B1; Cyclin-Dependent Kinase In | 2012 |
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Car | 2013 |
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Topics: Active Transport, Cell Nucleus; Anti-Infective Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Ce | 2004 |
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Surviva | 2004 |
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small | 2005 |
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
Topics: Acetylation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Ce | 2006 |
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tu | 2006 |
Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Non-Small-Cell Lung; Casp | 2008 |
Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis.
Topics: Active Transport, Cell Nucleus; Axin Protein; Azacitidine; beta Catenin; beta-Transducin Repeat-Cont | 2008 |